Selank side effects: what studies, labels and regulators have recorded

Evidence limits

What is not known about Selank's safety?

That gap cuts both ways. It does not show harm, and it does not show safety. A record that is missing is only a missing record, and everything below should be read with that in mind.

What side effects were recorded in human studies of Selank?

A 2015 comparison of 70 patients with anxiety disorders (30 given phenazepam alone, 40 given phenazepam with Selank) measured side effects on the UKU scale (a standard side-effect rating scale) and reported that phenazepam's own side effects, including sedation, attention and memory impairment and asthenia (weakness), were lower in the group that also received Selank; the abstract gives no counts and names no side effect of Selank itself (Medvedev et al., Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2015). A 2014 comparison of 60 patients with phobic-anxiety and somatoform disorders, with phenazepam as the comparator, also assessed tolerability, but its abstract reports no side-effect results (Medvedev et al., 2014).

Semax is the peptide most often named beside Selank. A 2020 imaging study of 52 healthy people compared Semax, Selank and placebo, and its abstract reports brain-connectivity results with no adverse-event data (Panikratova et al., Doklady Biological Sciences, 2020). No study read for this page tested the two together as a pair, so a combined side-effect record does not exist in the sources read.

What adverse reactions does the Russian product label list for Selank?

The Russian product label for Selank nasal drops, a registered medicine in Russia, lists allergic reactions (including delayed ones) and an unpleasant taste when drops reach the throat, both with frequency unknown. The label says no overdose cases have been registered and that no interaction was established with haloperidol, pentobarbital, hexobarbital, analeptics or ethanol. It states that the preservative methylparaben may cause allergic reactions. The text is reproduced on the RLS drug encyclopaedia, page changed 15 July 2025.

A label records what the manufacturer and the Russian regulator list. It is not an independent trial, and this page found no study behind its frequency statements. The label also gives pharmacokinetic figures that the Selank pharmacokinetics page reads separately.

Which contraindications does the Russian label list for Selank?

The Russian label lists four contraindications for Selank nasal drops: hypersensitivity to the active substance or any ingredient, pregnancy, breastfeeding, and age under 18. For the last three, the label's stated reason is that clinical studies were not done, not that harm was found. No TGA or FDA list of contraindications for Selank was found in the pages read for this page. ARTG status was not checked for this page, and searches of Drugs@FDA data and DailyMed on 14 October 2026 returned no Selank drug record (the legal-status page gives the searches). In mouse embryonic stem cells, a cell model that is not a pregnancy and does not establish a human result, Selank lowered the share of GABA-producing neurons by 61% at one concentration, and the authors concluded the tested peptides were not toxic during embryonic and fetal development (Kobylyanskii et al., 2017).

Cells in a dish are not a pregnancy. The stem-cell result is a model finding, and the label's pregnancy entry rests on the absence of human studies. Both facts point the same way: the question has not been answered in people.

What does the FDA say about Selank's safety?

The FDA's compounding page lists 'Selank acetate (TP-7)' in its table of substances 'nominated but withdrawn'. It states that compounded drugs containing selank acetate 'may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities', and that 'FDA lacks important information regarding any safety issues raised by selank acetate administered to humans' (FDA, content current as of 22 April 2026, read 14 October 2026). Immunogenicity means a risk that the immune system reacts to the peptide. No Selank drug record was found in Drugs@FDA data or DailyMed in the searches of 14 October 2026.

The FDA wording describes a regulatory review of compounding, not a clinical trial. The legal-status page sets out the full FDA record, including the database searches.

Is Selank safe?

No document read for this page declares Selank safe or unsafe for people. The evidence is thin and mixed in kind: tolerability words in Russian patient studies, a Russian label listing allergic reactions and taste change, an FDA statement that safety information is lacking, and laboratory findings. The TGA says unapproved peptide products 'have not been evaluated for safety, quality or effectiveness by the TGA' (TGA advisory, 13 April 2026). That advisory names other peptides as examples and does not name Selank.

'Safe' is a verdict, and verdicts come from regulators weighing trial data. For Selank, no regulator the page could read has issued one. The records here are a map of what was reported, with the blank areas marked.

What laboratory and animal safety findings exist for Selank?

In anaesthetised male cats, with no count in the abstract, intravenous Selank was followed by a 32% fall in arterial pressure for the first one to three minutes, a 24% rise in cerebral blood flow for five to ten minutes and no change in heart or breathing rate; this is an animal result under anaesthesia and does not show the same in people (Gan'shina and Kozlovskii, 2005). In a laboratory thromboelastography test (a blood-clotting test), Selank moved clotting measures toward hypocoagulation, the strongest effect of three peptides tested, in blood samples with no count in the abstract and with no human outcome, which does not establish a human result (Rogozinskaya and Lyapina, Bulletin of Experimental Biology and Medicine, 2017).

None of these results was followed up with human outcomes in the records read, so the clotting finding stays a laboratory observation. The cat study used anaesthetised animals and an intravenous route, which differs from the nasal route in the patient studies.

Has Selank been found in seized or unregulated products?

Yes. At the end of 2017 and again in 2018, Belgian laboratory analysts found Selank and Semax in two suspicious preparations, then built a mass-spectrometry method to detect ten such research peptides sold online; the finding shows presence in those two preparations and not how common such products are (Vanhee et al., Drug Testing and Analysis, 2020). The authors write that, to their knowledge, the two peptides have not completed any clinical trials, and they describe such molecules as potentially dangerous (Vanhee et al., 2020). The TGA adds that labelling on unapproved peptide products may be inaccurate, so users may not have reliable information about ingredients (TGA advisory, 13 April 2026).

Contents are a safety question of their own. A side-effect record for a studied peptide says nothing about an unlabelled mixture. The Selank reference material page describes research material, not a medicine. How to read a certificate of analysis explains what a batch report can and cannot show.